Net Income

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Facing an OSC probe and audit delays, the legal tech firm is now seeking court relief, raising red flags for investors about its governance and finances.

Toro's acquisition of Tornado isn't just about new machinery; it's a calculated move to capture the booming, safety-critical underground excavation market.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Global Ship Lease's steady dividend is more than investor news; it reveals deep insights into containership market health and strategic resilience.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

A junior miner's historic regulatory win in Oregon could set a new precedent for resource development, balancing economic promise with environmental rigor.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

A food-tech firm's pivot from quiet operator to public force reveals a savvy digital strategy, a key US acquisition, and a plan to dominate the 'better-for-you' market.

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

Wrapbook's acquisition of scheduling platform Cinapse promises to end decades of fragmented workflows, creating a single system for planning and payroll.

Beyond the lavish anniversary party, the Chinese spirits giant is leveraging a century of history in a sophisticated bid to conquer the Western market.

A new point-of-care PCR test is moving closer to reality in India, promising to revolutionize the fight against tuberculosis and cervical cancer.

With a new SVP of Growth, John Henry, RestorixHealth signals an aggressive push in the booming wound care market, navigating tech shifts and regulatory hurdles.

Prospect Enhanced Yield Fund's debut 9% distribution tempts income seekers, but a look into the structured credit market reveals a complex risk-reward.